Department of Pharmacy, Kumamoto Red Cross Hospital, Nagamine-minami, Kumamoto, Japan.
Biol Pharm Bull. 2011;34(11):1765-8. doi: 10.1248/bpb.34.1765.
Although gemcitabine is frequently used in the treatment of cancer, it is associated with myelosuppression. An animal study showed that the tolerability of gemcitabine varied with changes in treatment time; however, no clinical data have verified this finding. The purpose of this study was to determine the relationship between treatment time and development of hematologic toxicity in patients treated with gemcitabine. Gemcitabine-induced hematologic toxicity was retrospectively investigated in 77 patients. Patients were divided into two treatment-time groups: 9:00 and 15:00. Hematologic toxicity was evaluated on day 8 and 15 after treatment. On day 8 and 15, the changing count of white blood cells was significantly reduced in patients treated at 15:00 compared with those treated at 9:00 (p<0.01 and p<0.05, respectively). On days 8 and 15, the changing count of platelet was significantly reduced in patients treated at 15:00 compared with those treated at 9:00 (p<0.05). The incident of over common terminology criteria for adverse events (CTCAE) grade 2 white blood cell decreased was significantly reduced in patients treated at 15:00 compared with those treated at 9:00 (p=0.048, odds ratio=2.92). In conclusion, this cohort study demonstrated that gemcitabine-induced hematologic toxicity could be alleviated by treating patients at 9:00.
虽然吉西他滨常用于癌症治疗，但它与骨髓抑制有关。一项动物研究表明，吉西他滨的耐受性随治疗时间的变化而变化；然而，没有临床数据证实这一发现。本研究旨在确定吉西他滨治疗时间与患者血液毒性发展之间的关系。本研究回顾性调查了 77 例接受吉西他滨治疗的患者的吉西他滨诱导的血液毒性。患者分为两组：9:00 和 15:00。在治疗后第 8 天和第 15 天评估血液毒性。第 8 天和第 15 天，15:00 组治疗患者的白细胞计数变化明显低于 9:00 组（p<0.01 和 p<0.05）。第 8 天和第 15 天，15:00 组治疗患者的血小板计数变化明显低于 9:00 组（p<0.05）。与 9:00 组相比，15:00 组治疗患者中常见不良事件术语标准（CTCAE）分级 2 级以上白细胞减少症的发生率显著降低（p=0.048，优势比=2.92）。总之，这项队列研究表明，在 9:00 治疗患者可以减轻吉西他滨引起的血液毒性。
